Scalper1 News
Novo Nordisk (NVO) stock rose sharply Friday after the Danish maker of diabetes therapies said it successfully completed a phase 2 trial for a new oral diabetes drug that could mark a milestone in diabetes therapy. The drug, called OG217SC, is used for type 2 diabetes. It is an oral version of Novo’s semaglutide, a once-weekly GLP-1 (Glucagon-like peptide-1) analogue. Each drug works to promote the body’s natural production of insulin as a way of Scalper1 News
Scalper1 News